ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ELEV Elevation Oncology Inc

4,0485
0,4985 (14,04%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Elevation Oncology Inc ELEV NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,4985 14,04% 4,0485 01:05:31
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,59 3,43 4,48 4,00 3,55
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.4.202422:30PRNUSElevation Oncology Presents Preclinical Proof-of-Concept..
06.3.202414:14EDGAR2Form S-8 - Securities to be offered to employees in employee..
06.3.202413:45EDGAR2Form 8-K - Current report
06.3.202413:30PRNUSElevation Oncology Reports Fourth Quarter and Full Year 2023..
06.3.202413:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05.3.202422:50PRNUSElevation Oncology to Present Preclinical Proof-of-Concept..
04.3.202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
04.3.202413:30PRNUSElevation Oncology Appoints Experienced Clinical Development..
28.2.202413:30PRNUSElevation Oncology to Participate in Upcoming Investor..
22.2.202413:30PRNUSElevation Oncology Expands Ongoing Phase 1 Clinical Trial of..
20.2.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23.1.202422:15EDGAR2Form 8-K - Current report
22.1.202422:57EDGAR2Form SC 13G - Statement of acquisition of beneficial..
22.1.202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.1.202422:24EDGAR2Form 3 - Initial statement of beneficial ownership of..
22.1.202413:45EDGAR2Form 8-K - Current report
22.1.202413:30PRNUSElevation Oncology Announces Appointment of Darcy Mootz,..
09.1.202422:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05.1.202413:40EDGAR2Form 8-K - Current report
05.1.202413:30PRNUSElevation Oncology Announces Program Updates and Upcoming..
22.11.202313:30PRNUSElevation Oncology to Present at the Piper Sandler 35th..
02.11.202312:45EDGAR2Form 8-K - Current report
02.11.202312:30PRNUSElevation Oncology Reports Third Quarter 2023 Financial..
02.11.202312:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22.9.202322:30EDGAR2Form 8-K - Current report
05.9.202313:30PRNUSElevation Oncology to Present at the H.C. Wainwright 25th..
16.8.202313:45EDGAR2Form 8-K - Current report
16.8.202313:30PRNUSElevation Oncology Announces First Patient Dosed in the..
03.8.202313:45EDGAR2Form 8-K - Current report
03.8.202313:30PRNUSElevation Oncology Reports Second Quarter 2023 Financial..
03.8.202313:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03.8.202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.7.202322:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.7.202322:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
13.7.202314:15EDGAR2Form 8-K - Current report
13.7.202314:00PRNUSElevation Oncology Appoints Joseph Ferra as Chief Executive..
09.6.202304:41PRNUSElevation Oncology Announces Pricing of $50 Million Public..
08.6.202322:01PRNUSElevation Oncology Announces Launch of Proposed Public..
03.6.202315:00PRNUSElevation Oncology Highlights First-in-Human Phase 1..
15.5.202313:30PRNUSElevation Oncology Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock